Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Financial incentives to promote personalized medicine in Europe: an overview and guidance for implementation

Journal article

Koleva-Kolarova R. et al, (2023), Personalized Medicine

IT Evaluation of Foundation Healthcare Group NHS Vanguard programme: IT simultaneously an enabler and a rate limiting factor.

Journal article

Tapuria A. et al, (2022), Informatics for health & social care, 47, 317 - 325

REIMBURSEMENT PATHWAY FOR ADVANCED THERAPY MEDICINAL PRODUCTS IN BULGARIA

Conference paper

Djambazov S. et al, (2022), VALUE IN HEALTH, 25, S472 - S472

TARGETED AND IMMUNOTHERAPIES FOR CANCER - REIMBURSEMENT AND EXPENDITURE IN A SINGLE-PAYER HEALTHCARE SYSTEM IN BULGARIA

Conference paper

Encheva-Malinova M. et al, (2022), VALUE IN HEALTH, 25, S477 - S477

Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options Article

Journal article

Koleva-Kolarova R. et al, (2022), Applied Health Economics and Health Policy

WHAT IS THE NET ADDED VALUE OF PERSONALISED MEDICINE? A SYSTEMATIC LITERATURE REVIEW

Conference paper

Vellekoop H. et al, (2022), VALUE IN HEALTH, 25, S75 - S75

Load More